BioCentury | Mar 20, 2018
Distillery Therapeutics

Cancer

...cell carcinoma (BCC) Cell culture and mouse studies suggest inhibition of SRF or its co-activator MLK1...
...BCC. In one human and two mouse SMO inhibitor-resistant BCC cell lines, a tool compound MLK1...
...Next steps could include testing MLK1 inhibition in models of other SMO inhibitor-resistant cancers. TARGET/MARKER/PATHWAY: Megakaryoblastic leukemia translocation 1 (MLK1)...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Cognitive dysfunction Mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) Cell culture and mouse studies suggest the MLK3 inhibitor URMC-099 could be used to treat...
BioCentury | Feb 7, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Mixed lineage kinase 4 (KIAA1804; MLK4); K-Ras An in vitro and mouse study suggests inhibiting MLK4 could help treat...
BioCentury | Oct 20, 2011
Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease FYVE, RhoGEF and PH domain containing 1 (FGD1); mitogen-activated protein kinase kinase kinase 11 (MAP3K11; MLK3) Studies in...
BioCentury | Jun 12, 2008
Targets & Mechanisms

Eyeing New Uses for Protease Inhibitors

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis. 1 The...
BioCentury | Jul 3, 2006
Product Development

Asthma roadMAP

deCode genetics Inc. says population genetics work showing that MAP kinase is an important factor in asthma enabled the company to repurpose a failed Parkinson's disease product from Cephalon Inc. DCGN reported positive data on...
BioCentury | Jul 3, 2006
Clinical News

CEP-1347: Phase IIa data

Data from a Phase IIa trial showed that CEP-1347 improved measures of lung function, including methacholine challenge and peak expiratory flow rate. The compound also showed improvement in biomarkers associated with asthma severity and inflammation....
BioCentury | May 16, 2005
Clinical News

CEP-1347: Phase II/III discontinued

An independent data safety monitoring committee recommended discontinuation of a double-blind, placebo-controlled, North American Phase II/III trial in 800 patients to treat PD with CEP-1347.The committee concluded that final data would not likely provide evidence...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
BioCentury | Aug 5, 2002
Clinical News

CEP-1347: Started Phase II-II

Cephalon Inc. (CEPH),West Chester, Penn. H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Product: CEP-1347 Business: Neurological Therapeutic category: Neuroprotectant Target: Kinases Description: Mixed lineage kinase (MLK) inhibitor of c- Jun N-terminal kinase ( JNK ) activation Indication: Treat...
Items per page:
1 - 10 of 11